IPA ImmunoPrecise Antibodies Ltd. Stock Quote

IPA [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	6.73%	Shs Outstand	19.08M	Perf Week	-19.17%
Market Cap	127.07M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	17.07M	Perf Month	9.18%
Income	-	PEG	-	EPS next Q	-	Inst Own	7.21%	Short Float	0.79%	Perf Quarter	-27.84%
Sales	17.18M	P/S	7.40	EPS this Y	-	Inst Trans	-	Short Ratio	0.06	Perf Half Y	-59.19%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	22.20%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	5.00 - 33.34	Perf YTD	-55.45%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-79.06%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	39.60%	ATR	1.21
Employees	-	Current Ratio	-	Sales Q/Q	11.90%	Oper. Margin	-	RSI (14)	50.42	Volatility	11.68% 16.75%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.80	Prev Close	6.66
Shortable	Yes	LT Debt/Eq	-	Earnings	Jul 28 AMC	Payout	-	Avg Volume	2.23M	Price	6.98
Recom	-	SMA20	5.83%	SMA50	1.66%	SMA200	-30.19%	Volume	848,543	Change	4.80%

Jul-28-21 08:02AM	ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021 Business Wire -6.46%
Jul-22-21 08:02AM	ImmunoPrecise's PolyTope TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays Business Wire +136.49%
Jul-20-21 04:53AM	Should ImmunoPrecise Antibodies (CVE:IPA) Be Disappointed With Their 23% Profit? Simply Wall St.
Jul-15-21 08:08AM	ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021 Business Wire
Jun-22-21 08:28AM	Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform PR Newswire
08:28AM	Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform Business Wire
Jun-17-21 08:28AM	Histopathology Preclinical Data from ImmunoPrecises Polytope Program Confirms Lung Inflammation Reduction Business Wire
Jun-15-21 08:28AM	Preclinical Data from ImmunoPrecises Drug Pipeline to be Presented During the BIO International Partnering Event Business Wire
Jun-02-21 09:05PM	ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche Business Wire
May-25-21 08:28AM	ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board Business Wire
May-20-21 07:28AM	ImmunoPrecise Moves SARS-CoV-2 PolyTope Cocktail Programs Path Toward IND Filing Business Wire +7.28%
Apr-21-21 08:28AM	ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record Business Wire +6.18%
Apr-08-21 08:02AM	ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimers Disease Business Wire +7.94%
Mar-25-21 09:03AM	ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern Business Wire
Mar-17-21 06:48PM	ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year Business Wire
Mar-16-21 07:29AM	ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies Business Wire
Mar-04-21 07:28AM	ImmunoPrecise Announces Participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021 (Virtual Conference) Business Wire -8.84%
Feb-19-21 07:28AM	ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope Monoclonal Antibody Cocktail Candidate Against COVID-19 Business Wire
Feb-13-21 01:25AM	TSX Venture Exchange Stock Maintenance Bulletins CNW Group
Feb-10-21 06:54PM	IPA Announces Closing of Over-Allotment Option Associated with the Recently Completed Bought Deal Offering of Common Shares Business Wire
Feb-08-21 04:01PM	IPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares Business Wire
Feb-03-21 10:50PM	IPA Increases Previously Announced Bought Deal Offering of Common Shares to $21.7 Million Business Wire
05:55PM	IPA Announces $10.0 Million Bought Deal Offering of Common Shares Business Wire
Jan-18-21 07:44AM	If You Had Bought ImmunoPrecise Antibodies (CVE:IPA) Shares Three Years Ago You'd Have Earned 555% Returns Simply Wall St.
Jan-06-21 10:34PM	ImmunoPrecise Antibodies Announces Grant of Stock Options Business Wire
07:45AM	ImmunoPrecise Antibodies to Participate in January Conferences Business Wire

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production and screening; hybridoma production with screening and clone-picking; transgenic animals and multi-species antibody discovery; antibody characterization studies, such as affinity measurements, functional assays and epitope mapping, and binning; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA synthesis and cloning, protein and antibody downstream processing; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; and cryopreservation. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience